alirocumab SAR236553 (REGN727)
POP12671
Phase 3 small_molecule completed
Quick answer
alirocumab SAR236553 (REGN727) for Hypercholesterolemia is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 8 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Hypercholesterolemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed